Abstract

Chimeric parainfluenza viruses (PIVs) are provided that incorporate a PIV vector genome or antigenome and one or more antigenic determinant(s) of a heterologous PIV or non-PIV pathogen. These chimeric viruses are infectious and attenuated in humans and other mammals and are useful in vaccine formulations for eliciting and immune responses against one or more PIVs, or against a PIV and non-PIV pathogen. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric PIV genome or antigenome which includes a partial or complete PIV vector genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) encoding antigenic determinant(s) of a heterologous PIV or non-PIV pathogen. In preferred aspects of the invention, chimeric PIV incorporate a partial or complete human PIV vector genome or antigenome combined with one or more heterologous gene(s) or genome segment(s) from a heterologous PIV or non-PIV pathogen, wherein the chimeric virus is attenuated for use as a vaccine agent by any of a variety of mutations and nucleotide modifications introduced into the chimeric genome or antigenome.


Claims
CPC Classifications
Download PDF
Document Preview
Document History
  • Publication: Jan 1, 2008
  • Application: Dec 10, 1999
    US US 45881399 A
  • Priority: Dec 10, 1999
    US US 45881399 A
  • Priority: May 22, 1998
    US US 8379398 A
  • Priority: Sep 19, 1997
    US US 5938597 P
  • Priority: May 23, 1997
    US US 4757597 P

Download Citation


Sign in to the Lens

Feedback